HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
May 03, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, May 03, 2022 (GLOBE NEWSWIRE) -- New York, US and Vienna, Austria, May 2, 2022 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of...
HOOKIPA announces promotion of Christine D. Baker to Chief Operating Officer
May 02, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, May 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Appoints Tim Reilly, Ph.D. to its Board of Directors
April 20, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, April 20, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
New data show HOOKIPA’s arenaviral immunotherapies induce potent T cell responses in novel combinations and against tumor self-antigens
April 13, 2022 11:01 ET
|
HOOKIPA Pharma Inc.
Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor controlPreclinical data also expand evidence on...
HOOKIPA to Participate in the Kempen Life Sciences Conference
April 13, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, April 13, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Outlook
March 24, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
Lead oncology candidate HB-200 demonstrated high antigen-specific T cell responses and encouraging anti-tumor activity in heavily pre-treated head and neck cancer patientsHOOKIPA received FDA Fast...
HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
March 22, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 22, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
March 17, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
March 08, 2022 16:51 ET
|
HOOKIPA Pharma Inc.
Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitorsPreclinical data suggest synergy of arenaviral...
HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
March 02, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...